


CORRECTION

Open Access



Correction: Novel engineered IL-2 Nemvaleurin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy

Kewen He^{1,2*} , Nahum Puebla-Osorio², Hampartsoum B. Barsoumian², Duygu Sezen^{2,3}, Zahid Rafiq², Thomas S. Riad², Yun Hu², Ailing Huang², Tiffany A. Voss², Claudia S. Kettlun Leyton², Lily Jae Schuda², Ethan Hsu², Joshua Heiber⁴, Maria-Angelica Cortez² and James W. Welsh^{2*}

Correction: *J Exp Clin Cancer Res* 43, 251 (2024)

<https://doi.org/10.1186/s13046-024-03165-x>

Following publication of the original article [1], the authors found an error in the affiliation of the 5th author, Zahid Rafiq. He was mistakenly assigned to Affiliation 1. The details are given below:

Incorrect affiliation:

¹ Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.

Correct affiliation:

² Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

This correction does not affect the overall result or conclusion of the article. The original article [1] has been corrected.

Published online: 10 September 2024

Reference

1. He K, Puebla-Osorio N, Barsoumian HB, et al. Novel engineered IL-2 Nemvaleurin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. *J Exp Clin Cancer Res.* 2024;43:251. <https://doi.org/10.1186/s13046-024-03165-x>.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1186/s13046-024-03165-x>.

*Correspondence:

Kewen He
hekewen9144@foxmail.com
James W. Welsh
jwelsh@mdanderson.org

¹Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China

²Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

³Department of Radiation Oncology, Koç University School of Medicine, Istanbul, Turkey

⁴Mural Oncology PLC, Waltham, MA, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.